PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34257712-9	2021	Fedratinib (a JAK2 inhibitor) further strengthened the alleviative effects of ZKPC on bronchial asthma.	Fedratinib	0-10	Janus kinase 2	Mus musculus	14-18	
34145036-2	2021	The JAK2 inhibitors Ruxolitinib and Fedratinib have been approved for treatment of MF, but they do not offer significant improvement of bone marrow fibrosis.	Fedratinib	36-46	Janus kinase 2	Mus musculus	4-8	
33542546-2	2021	MPN treatment options currently mainly consist of cytoreductive therapy with hydroxyurea and JAK2 inhibitors such as ruxolitinib and fedratinib.	Fedratinib	133-143	Janus kinase 2	Mus musculus	93-97	
32086626-7	2020	METHODS: A selective JAK2 inhibitor TG101348 (fedratinib) or vehicle was given to high-fat high-cholesterol Western diet (WD)-fed wild-type (WT) or Apoe-/- mice.	Fedratinib	36-44	Janus kinase 2	Mus musculus	21-25	
32647323-4	2021	In mouse models of JAK2V617F-driven myeloproliferative disease, fedratinib blocked phosphorylation of STAT5, increased survival, and improved MF-associated disease features, including reduction of white blood cell counts, hematocrit, splenomegaly, and fibrosis.	Fedratinib	64-74	Janus kinase 2	Mus musculus	19-23	
31100032-0	2019	TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo.	Fedratinib	0-8	Janus kinase 2	Mus musculus	22-26	
31100032-4	2019	However, in this study, we have investigated the effect of selective JAK2 antagonist TG101348 in fibroblasts and inflammatory macrophages and in vivo in an acute carbon tetrachloride-induced liver injury mouse model.	Fedratinib	85-93	Janus kinase 2	Mus musculus	69-73	
26176817-3	2015	Therefore, we decided to compare in mice the effect of a JAK2 inhibitor, Fedratinib, in MPN models of increasing severity: polycythemia vera (PV), post-PV myelofibrosis (PPMF) and rapid post-essential thrombocythemia MF (PTMF).	Fedratinib	73-83	Janus kinase 2	Mus musculus	57-61	
28339658-5	2017	This activity could be completely blocked by the broad specificity tyrosine kinase inhibitor genistein at either stage, but only at the two-cell stage was there a substantial component of activity that was sensitive to low concentrations of the JAK2-selective inhibitors TG101348 or ruxolitinib.	Fedratinib	271-279	Janus kinase 2	Mus musculus	245-249	
27957861-2	2017	In this study, combined TKI ponatinib and JAK2 inhibitor SAR302503 short-term treatment effectively suppressed growth and promoted apoptosis of BaF3/T315I cells in cytokine-containing medium in vitro.	Fedratinib	57-66	Janus kinase 2	Mus musculus	42-46	
27957861-3	2017	SAR302503 prevented cytokine-dependent resistance to ponatinib via inhibition of JAK2/STAT5 phosphorylation.	Fedratinib	0-9	Janus kinase 2	Mus musculus	81-85	
24610827-3	2014	This prompted us to assess the activity of a clinical grade JAK2 selective inhibitor, fedratinib (SAR302503/TG101348), in in vitro and in vivo model systems of cHL and MLBCL with defined JAK2 copy numbers.	Fedratinib	86-96	Janus kinase 2	Mus musculus	60-64	
24610827-3	2014	This prompted us to assess the activity of a clinical grade JAK2 selective inhibitor, fedratinib (SAR302503/TG101348), in in vitro and in vivo model systems of cHL and MLBCL with defined JAK2 copy numbers.	Fedratinib	86-96	Janus kinase 2	Mus musculus	187-191	
24610827-3	2014	This prompted us to assess the activity of a clinical grade JAK2 selective inhibitor, fedratinib (SAR302503/TG101348), in in vitro and in vivo model systems of cHL and MLBCL with defined JAK2 copy numbers.	Fedratinib	98-107	Janus kinase 2	Mus musculus	60-64	
24610827-6	2014	There was an inverse correlation between 9p24.1/JAK2 copy number and the EC50 of fedratinib.	Fedratinib	81-91	Janus kinase 2	Mus musculus	48-52	
18394554-0	2008	Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.	Fedratinib	12-20	Janus kinase 2	Mus musculus	34-38	
18394554-1	2008	We report that TG101348, a selective small-molecule inhibitor of JAK2 with an in vitro IC50 of approximately 3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.	Fedratinib	15-23	Janus kinase 2	Mus musculus	65-69